Table 2.
Responses to questions regarding knowledge about the type of ADR to be reported and purpose of ADR reporting
| Frequency (%) | ||
|---|---|---|
| Yes | No | |
| Regarding type of ADR to be reported | ||
| 1. All suspected reactions to established drugs in new combination or for new indication should be reported | 85 (58.6) | 60 (41.4) |
| 2. All suspected reactions to new products should be reported | 106 (73.1) | 39 (26.9) |
| 3. Only serious reactions to new products should be reported | 66 (45.5) | 79 (54.5) |
| 4. All serious reactions to old & new products should be reported | 130 (89.7) | 15 (10.3) |
| 5. Only proven reactions should be reported | 67 (46.2) | 78 (53.8) |
| Following is/are the purpose(s) of the national ADR reporting scheme in Malaysia | ||
| 1. For identification of previously unrecognized ADRs | 109 (75.2) | 36 (24.8) |
| 2. To recognize factors predisposing to ADRs | 92 (63.4) | 53 (36.6) |
| 3. To characterize ADRs | 121 (83.4) | 24 (16.6) |
| 4. To enable toxicity of drugs in similar therapeutic classes to be compared | 133 (91.7) | 12 (8.3) |
| 5. To identify safe drugs | 121 (83.4) | 24 (16.6) |
| 6. To measure the incidence of ADRs | 133 (91.7) | 12 (8.3) |